Invasive mold infections: recent advances in management approaches

References

• Marr K A, Carter R A, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917
   PubMed Web of Science ®Google Scholar
• Baddley J W, Pappas P G, Smith A C, Moser S A. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol 2003; 41: 5525–5529
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr K A, Queitoz-Telles F, Martins C A, Trabasso P, Costa S. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237–1242
   PubMed Web of Science ®Google Scholar
• Pfaller M A, Diekema D J. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. International fungal surveillance participant group. Clin Micrbiol Infect 2004; 10(Suppl. 1)11–23
   PubMed Web of Science ®Google Scholar
• Kontoyiannis D P, Lionakis M S, Lewis R E, Chamilos G, Healy M, Perego C. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case–control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350–1360
   PubMed Web of Science ®Google Scholar
• Pfaller M A, Pappas P G, Wingard J R. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006; 43: S3–S14
   Web of Science ®Google Scholar
• Malani A N, Kauffman C A. Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007; 67: 1803–1812
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr K A. Emerging fungal diseases. Clin Infect Dis 2005; 41: 521–526
   PubMed Web of Science ®Google Scholar
• Marr K A. Invasive candida infections: the changing epidemiology. Oncology (Williston Park) 2004; 18(14 Suppl. 13)9–14
   PubMedGoogle Scholar
• Pfaller M A. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22(Suppl. 2)S89–S94
   PubMed Web of Science ®Google Scholar
• Baddley J W, Stroud T P, Salzman D, Pappas P G. Invasive mould infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319–1324
   PubMed Web of Science ®Google Scholar
• Myers J D. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17(Suppl. 6)10–13
   Google Scholar
• Shaukat A, Bakri F, Young P, Hahn T, Ball D, Baer M R. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathological characteristics. Mycopathologia 2005; 159: 181–188
   PubMed Web of Science ®Google Scholar
• Wald A, Leisenring W, van Burik J A, Bowden R A. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459–1466
   PubMed Web of Science ®Google Scholar
• Bakr M A. Induction therapy. Exp Clin Transplant 2005; 3: 320–328
   PubMedGoogle Scholar
• Jacobsohn D A. Emerging therapies for graft-versus-host disease. Expert Opin Emerg Drugs 2003; 8: 323–338
   PubMedGoogle Scholar
• Pérez-Simón J A, Sánchez-Abarca J I, Díez-Campelo M, Caballero D, San Miguel J. Chronic graft-versus-host disease: pathogenesis and clinical management. Drugs 2006; 66: 1041–1057
   PubMed Web of Science ®Google Scholar
• Remberger M, Aschan J, Barkholt L, Tollemar J, Ringdén O. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 2001; 15: 147–153
   PubMed Web of Science ®Google Scholar
• Simpson D. New developments in the prophylaxis and treatment of graft versus host disease. Expert Opin Pharmacother 2001; 2: 1109–1117
   PubMedGoogle Scholar
• Nath D S, Kandaswamy R, Gruessner R, Sutherland D E, Dunn D L, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc 2005; 37: 934–936
   PubMed Web of Science ®Google Scholar
• Rai K R, Freter C E, Mercier R J, Cooper M R, Mitchell B S, Stadtmauer E A, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891–3897
   PubMed Web of Science ®Google Scholar
• Couriel D R, Hicks K, Giralt S, Champlin R E. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol 2000; 12: 582–587
   PubMed Web of Science ®Google Scholar
• Marty F M, Lee S J, Fahey M M, Alyea E P, Soiffer R J, Antin J H, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a chart study. Blood 2003; 102: 2768–2776
   PubMed Web of Science ®Google Scholar
• Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007; 82: 45–52
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Samonis G, Boumpas D T, Kontoyiannis D P. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008; 83: 181–194
   PubMed Web of Science ®Google Scholar
• McCaul K G, Nevill T J, Barnett M J, Toze C L, Currie C J, Sutherland H J, et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000; 9: 367–374
   PubMedGoogle Scholar
• Mohty M, Jacot W, Faucher C, Bay J O, Zandotti C, Collet L, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003; 17: 2168–2177
   PubMed Web of Science ®Google Scholar
• Neuhaus P, Clavien P A, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al. CHIC 304 International Liver Study Group. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8: 132–142
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Yussim A, Cambi V, Legendre C, Rizzo G, Salvadori M, et al. Simulect Phase IV Study Group. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001; 72: 1261–1267
   PubMed Web of Science ®Google Scholar
• Helbig G, Stella-Holowiecka B, Krawczyk-Kulis M, Wojnar J, Markiewicz M, Wojciechowska-Sadus M, et al. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Haematologica 2005; 90: ECR33
   PubMedGoogle Scholar
• Marty F M, Lowry C M, Cutler C S, Campbell B J, Fiumara K, Baden L R, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 552–559
   PubMed Web of Science ®Google Scholar
• Giles F J. Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants. Clin Infect Dis 1998; 26: 1282–1289
   PubMed Web of Science ®Google Scholar
• Rowe J M. Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections. Clin Infect Dis 1998; 26: 1290–1294
   PubMed Web of Science ®Google Scholar
• Sung L, Nathan P C, Alibhai S M, Tomlinson G A, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 1007; 147: 400–411
   Google Scholar
• Marr K A, Carter R A, Boeckh M. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and rick factors. Blood 2002; 100: 4358–4366
   PubMed Web of Science ®Google Scholar
• Junghanss C, Marr K A, Carter R A, Sandmaier B M, Maris M B, Maloney D G, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8: 512–520
   PubMed Web of Science ®Google Scholar
• Pappas P G, Alexander B, Marr K, Kontoyiannis D P, Hadley S, Ito J, et al. Invasive fungal infections (IFIs) in hematopoietic stem cell (HSCTs) and organ transplant recipients (OTRs): overview of the TRANSNET database. In Program and abstracts of the 42nd annual meeting of the infectious diseases society of America (Boston), Alexandria, VA. Infectious Diseases Society of America, 2004; 174, Abstract no. 671
   Google Scholar
• McNeil M M, Nash S L, Hajjeh R A, Phelan M A, Conn L A, Plikaytis B D, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 2001; 33: 641–647
   PubMed Web of Science ®Google Scholar
• Perfect J R, Cox G M, Lee J Y, Kauffman C A, de Repentigny L, Chapman S W, , Mycoses Study Group, et al. The impact of culture isolation of aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33: 1824–1833
   PubMed Web of Science ®Google Scholar
• Balajee S A, Weaver M, Imhof A, Gribskov J, Marr K A. Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother 2004; 484: 1197–1203
   Web of Science ®Google Scholar
• Pavie J, Lacroix C, Hermoso D G, Robin M, Ferry C, Bergeron A, et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 2005; 43: 4902–4904
   PubMed Web of Science ®Google Scholar
• Lionakis M S, Lewis R E, Torres H A, Albert N D, Raad I I, Kontoyiannis D P. Increased frequency of non-fumigatus aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005; 52: 15–20
   PubMed Web of Science ®Google Scholar
• Panackal A A, Imhof A, Hanley E W, Marr K A. Aspergillus ustus infections among transplant recipients. Emerg Infect Dis 2006; 12: 403–408
   PubMed Web of Science ®Google Scholar
• Ader F, Nseir S, Le Berre R, Leroy S, Tillie-Leblond I, Marquette C H, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect 2005; 11: 427–429
   PubMed Web of Science ®Google Scholar
• Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45: 205–216
   PubMed Web of Science ®Google Scholar
• Chayakulkeeree M, Ghannoum M A, Perfect J R. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006; 25: 215–229
   PubMed Web of Science ®Google Scholar
• Roden M M, Zaoutis T E, Buchanan W L, Knudsen T A, Sarkisova T A, Schaufele R L, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653
   PubMed Web of Science ®Google Scholar
• Marty F M, Cosimi L, Baden L R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952
   PubMed Web of Science ®Google Scholar
• Ritz N, Ammann R A, Aebischer C C, Gugger M, Jaton K, Schmid R A, et al. Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child. Eur J Pediatr 2005; 164: 231–235
   PubMed Web of Science ®Google Scholar
• Trifilio S M, Bennett C L, Yarnold P R, McKoy J M, Parada J, Mehta J, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425–429
   PubMed Web of Science ®Google Scholar
• Walsh T J, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10(Suppl. 1)48–66
   PubMed Web of Science ®Google Scholar
• Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002; 49(Suppl. 1)7–10
   PubMed Web of Science ®Google Scholar
• Masia Canuto M, Gutierrez Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002; 2: 550–563
   PubMed Web of Science ®Google Scholar
• Steinbach W J, Perfect J R. Scedosporium species infections and treatments. J Chemother 2003; 15(Suppl. 2)16–27
   PubMed Web of Science ®Google Scholar
• Alexander B D, Pfaller M A. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006; 43(Suppl. 1)S15
   Web of Science ®Google Scholar
• Walsh T J, Anaissie E J, Denning D W, Herbrecht R, Kontoyiannis D P, , Infectious Diseases Society of America, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327–360
   PubMed Web of Science ®Google Scholar
• Caillot D, Couaillier J F, Bernard A, Casasnovas O, Denning D W, Mannone L, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253–259
   PubMed Web of Science ®Google Scholar
• Meersseman W, Vandecasteele S J, Wilmer A, Verbeken E, Peetermans W E, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170: 621–625
   PubMed Web of Science ®Google Scholar
• Segal B H, Walsh T J. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173: 707–717
   PubMed Web of Science ®Google Scholar
• Franquet T, Müller N L, Giménez A, Guembe P, de La Torre J, Baguó S. Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics 2001; 21: 825–837
   PubMed Web of Science ®Google Scholar
• Marr K A, Patterson T, Denning D. Aspergillosis: pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16: 875–894
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Perkhofer S, Nachbaur D, Auberger J, Freund M. The value of CT-guided lung biopsies in diagnosing invasive fungal infections: changing patterns and trends in diseases. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September, 17–202007. Chicago, IL, Abstract M-2023
   Google Scholar
• Sable C A, Strohmaier K M, Chodakewitz J A. Advances in antifungal therapy. Annu Rev Med 2008; 59: 361–379
   PubMed Web of Science ®Google Scholar
• Sulahian A, Touratier S, Brethon B, Peffault de LaTour R, Menotti J, DeRouin F, et al. Sodium gluconate containing parenteral nutrition solution as a cause of false positive Aspergillus galactomannan assay in pediatric patients. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, September, 17–202007, Abstract M-559
   Google Scholar
• Marr K A, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762–1769
   PubMed Web of Science ®Google Scholar
• Clancy C J, Jaber R A, Leather H L, Wingard J R, Staley B, Wheat L J, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45: 1759–1765
   PubMed Web of Science ®Google Scholar
• Husain S, Paterson D L, Studer S M, Crespo M, Pilewski J, Durkin M, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007; 83: 1330–1336
   PubMed Web of Science ®Google Scholar
• Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177: 27–34
   PubMed Web of Science ®Google Scholar
• Pazos C, Ponton J, Del Palacio A. Contribution of (1→3)-beta-d-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43: 299–305
   PubMed Web of Science ®Google Scholar
• Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A. Elevation of blood (1–3) beta-d-glucan concentrations in hemodialysis patients. Nephron 2001; 89: 15–19
   PubMed Web of Science ®Google Scholar
• Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in ICU patients. Clin Diagn Lab Immunol 2003; 10: 882–885
   PubMedGoogle Scholar
• Senn L, Robinson J O, Schmidt S, Knaup M, Asahi N, Satomura S, et al. 1,3-β-d-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46: 878–885
   PubMed Web of Science ®Google Scholar
• White P L, Linton C J, Perry M D, Johnson E M, Barnes R A. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42: 479–486
   PubMed Web of Science ®Google Scholar
• Wahba H, Truong M T, Lei X, Kontoyiannis D P, Marom E M. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis 2008; 46: 1733–1737
   PubMed Web of Science ®Google Scholar
• Panackal A A, Marr K A. Scedosporium/Pseudallescheria infections. Semin Respir Crit Care Med 2004; 25: 171–181
   PubMed Web of Science ®Google Scholar
• Boutati E I, Anaissie E J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90: 999–1008
   PubMed Web of Science ®Google Scholar
• Hachem R Y, Kontoyiannis D P, Boktour M R, Afif C, Cooksley C, Bodey G P, et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004; 101: 1594–1600
   PubMed Web of Science ®Google Scholar
• Dodds Ashley E S, Lewis R, Lewis J S, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43(Suppl. 1)S28
   Web of Science ®Google Scholar
• Pfaller M A, Diekema D J. Rare and emerging opportunistic fungal pathogens: concerns for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419–4431
   PubMed Web of Science ®Google Scholar
• Gonzalez C E, Rinaldi M G, Sugar A M. Zygomycosis. Infect Dis Clin North Am 2002; 16: 895–914
   PubMed Web of Science ®Google Scholar
• Spellberg B, Edwards J, Jr., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556–569
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Marr K A, Rex J H, Cohen S H. Amphotericin B: time for a new ‘gold standard’. Clin Infect Dis 2003; 37: 415–425
   PubMed Web of Science ®Google Scholar
• Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002; 49(Suppl. 1)31–36
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201–211
   PubMed Web of Science ®Google Scholar
• Alexander B D, Schell W A, Miller J L, Long G D, Perfect J R. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005; 80: 868–871
   PubMed Web of Science ®Google Scholar
• Verweij P E, Mellado E, Melchers W J. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356: 1481–1483
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Meletiadis J W, Mouton J W, Meis J F, Verweij P E, Eurofung Network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45–52
   PubMed Web of Science ®Google Scholar
• Sun Q N, Fothergill A W, McCarthy D I, Rinaldi M G, Graybill J R. In vitro activities of posaconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581–1582
   PubMed Web of Science ®Google Scholar
• Tobón A M, Arango M, Fernández D, Restrepo A. Mucormycosis (zygomycosis) in a heart–kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003; 36: 1488–1491
   PubMed Web of Science ®Google Scholar
• van Burik J A, Hare R S, Solomon H F, Corrado M L, Kontoyiannis D P. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61–e65, Erratum: Clin Infect Dis 2006;43:1376
   PubMed Web of Science ®Google Scholar
• Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27: 369–388
   PubMed Web of Science ®Google Scholar
• Hakki M, Staab J F, Marr K A. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50: 2522–2524
   PubMed Web of Science ®Google Scholar
• Hernandez S, López-Ribot J L, Najvar L K, McCarthy D I, Bocanegra R, Graybill J R. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004; 48: 1382–1383
   PubMed Web of Science ®Google Scholar
• Laverdière M, Lalonde R G, Baril J G, Sheppard D C, Park S, Perlin D S. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57: 705–708
   PubMed Web of Science ®Google Scholar
• Moudgal V, Little T, Boikov D, Vazquez J A. Multi echinocandin- and multi azole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49: 767–769
   PubMed Web of Science ®Google Scholar
• von Eiff M, Roos N, Schulten R, Hesse M, Zühlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62: 341–347
   PubMed Web of Science ®Google Scholar
• Greene R E, Schlamm H T, Oestmann J W, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373–379
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis R E, Kontoyiannis D P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503–509
   PubMed Web of Science ®Google Scholar
• Garey K W, Rege M, Pai M P, Mingo D E, Suda K J, Turpin R S, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25–31
   PubMed Web of Science ®Google Scholar
• Parkins M D, Sabuda D M, Elsayed S, Laupland K B. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60: 613–618
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242–1250
   PubMed Web of Science ®Google Scholar
• Wingard J R, Carter S L, Walsh T J, Kurtzberg J, Small T N, Gersten I D, et al. Results of a random, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood 2007; 110, Abstract 163
   Google Scholar
• Cornely O A, Maertens J, Bresnik M, Ebrahimi R, Ullmann A J, Bouza E, , AmBiLoad Trial Study Group, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289–1297
   PubMed Web of Science ®Google Scholar
• Perea S, Gonzalez G, Fothergill A W, Kirkpatrick W R, Rinaldi M G, Patterson T F. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of aspergillus spp. Antimicrob Agents Chemother 2002; 46: 3039–3041
   PubMed Web of Science ®Google Scholar
• Kirkpatrick W R, Perea S, Coco B J, Patterson T F. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564–2568
   PubMed Web of Science ®Google Scholar
• Marr K A, Boeckh M, Carter R A, Kim H W, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797–802
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal B H. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888–2897
   PubMed Web of Science ®Google Scholar
• Singh N, Limaye A P, Forrest G, Safdar N, Munoz P, Pursell K, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320–326
   PubMed Web of Science ®Google Scholar
• Spellberg B, Fu Y, Edwards J E, Jr., Ibrahim A S. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49: 830–832
   PubMed Web of Science ®Google Scholar
• Ibrahim A S, Gebremariam T, Fu Y, Edwards J E, Jr., Spellberg B. Combination echinocandin–polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008; 52: 1556–1558
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim A S, Edwards J, Jr., Filler S G, Goldberg R, et al. Combination polyene–caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364–371
   PubMed Web of Science ®Google Scholar
• Walsh T J, Hiemenz J W, Seibel N L, Perfect J R, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–1396
   PubMed Web of Science ®Google Scholar
• Perfect J R. Treatment of non-aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40(Suppl. 6)S401–S408
   PubMed Web of Science ®Google Scholar
• Perfect J R, Marr K A, Walsh T J, Greenberg R N, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122–1131
   PubMed Web of Science ®Google Scholar
• Malani A, Hmoud J, Chiu L, Carver P L, Bielaczyc A, Kauffman C A. Candida glabrata fungemia: experience in tertiary care center. Clin Infect Dis 2005; 41: 975–981
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Meis J F, Mouton J W, Rodriquez-Tudela J L, Donnelly J P, Verweij P E, EUROFUNG Network. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46: 62–68
   PubMed Web of Science ®Google Scholar